BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
Carbohydrate antigen 19-9 (CA 19-9), also known as sialyl Lewis A, is a glycolipid and O-linked glycoprotein embedded on the surface of cancer cells. It is synthesized by pancreatic cancer cells and is also produced by normal epithelial cells of the pancreas, bile ducts, stomach, and colon. CA 19-9, as the most commonly used and most effective serum tumor marker, can be used for the diagnosis and treatment of pancreatic cancer in symptomatic patients.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.